SCHAUMBURG, Ill., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ibandronate Sodium Injection, a bisphosphonate, in a preservative-free, prefilled plastic syringe kit. According to IMS, for the 12 months ending July 2014, the US market for Ibandronate approximated $18 million. As with all products in Sagent's portfolio, Ibandronate features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
"We are pleased to offer an additional source of Ibandronate Sodium Injection at market formation," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board of Sagent.
About Ibandronate Sodium Injection
Ibandronate Sodium Injection is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Ibandronate Sodium Injection increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.
The package insert, available at www.sagentpharma.com, contains the indications, complete side effect profile and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.